Literature DB >> 17720033

Understanding and treating "first-episode" schizophrenia.

Peter J Weiden1, Peter F Buckley, Michael Grody.   

Abstract

"First-episode schizophrenia" is a clinical and research term that often is used to emphasize the special issues that arise when working with this patient population. The notion that schizophrenia has an inexorable downhill course or is a deteriorating illness is being challenged by more sophisticated understanding of what happens before the initial episode and new understanding of the interactions between biologic vulnerabilities and specific environmental risk during adolescence and early adulthood, such as marijuana use. While the incidence rate of "first-episode" will make this a relatively small percentage of a usual clinical caseload, it is a critically important time for the future course of the illness. The hope is that proper management during this critical period will favorably influence the long-term trajectory of outcome for this individual patient. A growing body of evidence suggests that certain approaches and interventions are more helpful than others, such as understanding of the overwhelming nature of the experience to patients and families, aiming to achieve a full and broad pharmacologic response to initial antipsychotic therapy, while also being on the lookout for vulnerability and extreme sensitivity to side effects, and to anticipate a high likelihood of premature medication discontinuation. Clinicians and treatment services should try to identify "first-episode" patients in time to be able to anticipate and address these issues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720033     DOI: 10.1016/j.psc.2007.04.010

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  10 in total

1.  Schizophrenia: current concepts and approaches to patient care.

Authors:  Peter F Buckley; Adriana Foster
Journal:  Am Health Drug Benefits       Date:  2008-05

2.  Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.

Authors:  Ezequiel Uribe; Leticia Fernández; Dulce Pacheco; Luis Fernandez; Nieves Nayadoleni; Antonio Eblen-Zajjur
Journal:  J Neural Transm (Vienna)       Date:  2019-05-02       Impact factor: 3.575

Review 3.  Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.

Authors:  Peter F Whitty; Olabisi Owoeye; John L Waddington
Journal:  Schizophr Bull       Date:  2008-09-12       Impact factor: 9.306

4.  Neonatal Administration of Memantine Enhances Social Cognition in Adult Rats Subjected to Early Maternal Deprivation.

Authors:  Ezequiel Uribe; Eduardo Sánchez-Mendoza; Nayadoleni Nieves; Gustavo Merchor
Journal:  Exp Neurobiol       Date:  2016-12-09       Impact factor: 3.261

Review 5.  Diverse definitions of the early course of schizophrenia-a targeted literature review.

Authors:  Richard Newton; Alice Rouleau; Anna-Greta Nylander; Jean-Yves Loze; Henrike K Resemann; Sara Steeves; Benedicto Crespo-Facorro
Journal:  NPJ Schizophr       Date:  2018-10-15

6.  Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate.

Authors:  Francois-Pierre Joubert; Bonginkosi Chiliza; Robin Emsley; Laila Asmal
Journal:  S Afr J Psychiatr       Date:  2021-01-11       Impact factor: 1.550

7.  Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

Authors:  Jennifer Kern Sliwa; Cynthia A Bossie; Dong-Jing Fu; Ibrahim Turkoz; Larry Alphs
Journal:  Neuropsychiatr Dis Treat       Date:  2012-08-27       Impact factor: 2.570

8.  Risperidone long-acting injection: a review of its long term safety and efficacy.

Authors:  Michael K Rainer
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

9.  Complement system biomarkers in first episode psychosis.

Authors:  Maja Kopczynska; Wioleta Zelek; Samuel Touchard; Fiona Gaughran; Marta Di Forti; Valeria Mondelli; Robin Murray; Michael C O'Donovan; B Paul Morgan
Journal:  Schizophr Res       Date:  2017-12-24       Impact factor: 4.939

10.  Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease.

Authors:  Madis Parksepp; Liisa Leppik; Kadri Koch; Kärt Uppin; Raul Kangro; Liina Haring; Eero Vasar; Mihkel Zilmer
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.